-
41 new cases were confirmed on October 1, and 2 local cases were in Harbin
Time of Update: 2021-10-09
As of 24:00 on October 1, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are currently 890 confirmed cases (including 4 severe cases), a total of 90,677 cured and discharged cases, and a total of 4,636 deaths.
-
WHO: A total of 235673032 cases of new crown confirmed worldwide
Time of Update: 2021-10-09
According to the latest data from the WHO website, as of 20:48 on the 6th Central European Time (2:48 on the 7th, Beijing time), the number of confirmed cases worldwide increased by 39,964 compared with the day before, reaching 2,356,730,32; the number of deaths increased by 6,491, Reached 4,814,651 cases .
-
Why do we need to carry out booster immunization for key populations?
Time of Update: 2021-10-09
Detailed explanation by experts in disease control Why do we need to carry out booster immunization for key populations?
The relevant unit team in Guangdong has done research and can see that the vaccine protects the pneumonia caused by the new crown.
-
Summary of reissued materials by the Review Center
Time of Update: 2021-10-09
Please study the genotoxic impurities involved in the preparation of APIs in accordance with the requirements of the ICH M7 guidelines, and formulate reasonable control strategies in the API internal control standards based on the test results of multiple batches of samples .
-
Health Commission: 31 newly diagnosed cases on the 27th, including 13 from the local area
Time of Update: 2021-10-09
As of 24:00 on September 27, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are currently 982 confirmed cases (including 9 severe cases), a total of 90,463 cured and discharged cases, and a total of 4,636 deaths.
-
Experts' judgment: The epidemic in Heilongjiang has basically been effectively controlled
Time of Update: 2021-10-09
The risk of epidemic spillover has been basically eliminated The headquarter reporter learned from the press conference on the prevention and control of the new crown pneumonia epidemic in Heilongjiang Province that as of 24:00 on October 6, Heilongjiang Province had reported a total of 96 local positive infections, of which 89 were confirmed cases and 7 were asymptomatic infections.
-
The 26 newly confirmed cases on October 4 were all imported from abroad
Time of Update: 2021-10-09
As of 24:00 on October 4, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are currently 856 confirmed cases (including 3 severe cases), a total of 90,792 cured and discharged cases, and a total of 4,636 deaths.
-
"Common and frequently-occurring disease prevention research" and other 5 key special review lists
Time of Update: 2021-10-09
Attachment: List of review experts China Biotechnology Development Center 2021-09-30 Attachment: "Research on the Prevention and Control of Common and Frequent Diseases" and other 5 key special defense review experts list_2021930123328917.
pdf"Common and frequently-occurring disease prevention research" and other 5 key special defense review experts list_2021930123328917.
-
The international community should carry out traceability of the new coronavirus in many countries and places
Time of Update: 2021-10-09
For example, a retrospective survey study in The Lancet on January 24, 2020 showed that among the first batch of 41 cases of new coronary pneumonia confirmed by laboratories in Wuhan from December 16, 2019 to January 2, 2020 , The earliest case of symptoms can be traced back to December 1, 2019, and the patient has no history of exposure to the South China Seafood Market .
-
Determination of potential factors leading to severe new coronary pneumonia
Time of Update: 2021-10-09
High levels of CD47 protein can prevent an effective immune response, increase disease-related tissue and organ damage, or cause a higher severity of new coronary pneumonia .
-
Can buying a toothpaste kill Helicobacter pylori?
Time of Update: 2021-10-09
A recent interview with reporters discovered that "anti-pyloric toothpaste", which claims to be able to inhibit or even kill Helicobacter pylori, is quietly gaining popularity on the Internet .
-
Bozhiyan newly introduced two senior talents to create a leading drug delivery technology platform
Time of Update: 2021-10-09
Yang Ming will rely on forward-looking commercialization strategic thinking and market development experience to promote Bozhiyanxin's overall business operation capabilities, and build Bozhiyanxin into a leader in global drug research and development, and become the world's leading drug delivery technology platform company , To bring better medicines to the world .
-
Health Commission: 22 new confirmed cases, all imported from abroad
Time of Update: 2021-10-09
As of 24:00 on October 7, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are currently 786 confirmed cases (including 1 severe case), a total of 90,935 cured and discharged cases, and a total of 4,636 deaths.
-
Junshi Biologics submits Claudin 18.2 monoclonal antibody clinical application
Time of Update: 2021-10-02
2 is mainly expressed on differentiated epidermal cells of gastric mucosa in normal tissues, not on gastric stem cells, but in a variety of primary malignant tumors such as gastric cancer, pancreatic cancer, esophageal adenocarcinoma, colon cancer, liver cancer Abnormal activation and overexpression of Claudin 18.
-
Bankruptcy and reorganization of well-known pharmaceutical companies
Time of Update: 2021-10-02
How can Chinese medicine companies smoothly "turn over"01 Once tied with Tongrentang and Hu Qingyutang01 Once tied with Tongrentang and Hu QingyutangOn September 8, Qichacha APP showed that Guiyang Dechangxiang Pharmaceutical Co.
-
41 product specifications have a maximum drop of 99%!
Time of Update: 2021-10-02
Original research drugs or generic drugs (including reference preparations) that have passed the National Medical Products Administration's generic drug quality and efficacy consistency evaluation, this batch of centralized and large-volume procurement is temporarily not included, and the varieties that have been selected by national organizations and participating inter-provincial alliances are not included This time purchase with quantity .
-
The trend of drug bidding is clearly differentiated: volume purchase + price linkage!
Time of Update: 2021-10-02
The starting point for consideration of Heilongjiang’s idea is that if the nationwide exclusive packaging that is linked to this province is a small package, then based on the principle of price difference, then the price of the smallest unit of the large package must be relatively low, so that it can be as low as it is high.
-
Hisun Pharmaceutical's infliximab will be approved soon
Time of Update: 2021-10-02
On September 10, the NMPA official website showed that Hisun Pharmaceutical’s infliximab biosimilar entered the administrative approval stage and is expected to be approved in the near future .
-
Many provinces and cities have issued documents, and the transfer of local medical insurance supplements has entered a critical period
Time of Update: 2021-10-01
Among them, according to the notice issued by the Xinjiang Medical Insurance Bureau, it is clear that starting from January 1, 2022, the "Xinjiang Uygur Autonomous Region and Xinjiang Production and Construction Corps Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog" will be added to the non-ethnic medicines All 305 varieties were transferred out of the scope of medical insurance payment .
-
Domestic pharmaceutical companies are accelerating the improvement of innovation capabilities through "bringing in"
Time of Update: 2021-10-01
According to the terms of the agreement, Genting Shining will pay SinoVision and China Antibodies an advance payment of US$12 million and a total of US$549 million in future development, registration and commercialization milestone payments, as well as high single-digit global net sales.
